Related Experiment Video
Updated: May 12, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Metastatic Low-Grade Glioma Successfully Treated in a Pediatric Patient With BRAF A598_T599insI Mutation
Pierluigi Calò1, Safiatou Diallo1, Laetitia Lebrun2
1Department of Pediatric Oncology, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Hopital Universitaire Des Enfants Reine Fabiola, Brussels, Belgium.
Background:
Pediatric low-grade gliomas are common brain tumors often driven by MAPK pathway alterations, including rare BRAF mutations.
Case:
This case report describes the first use of treatment combining dabrafenib and trametinib in a 10-year-old boy with pleomorphic xanthoastrocytoma harboring a BRAF A598_T599insI mutation. Surgery and chemotherapy failed, leading to metastatic progression; yet targeted therapy has achieved a sustained clinical and radiological response, lasting more than 2 years.
Conclusion:
This case highlights the potential of RAF/MEK inhibitors in rare BRAF-mutated tumors and underscores the need for research to optimize treatment duration, manage side effects, and explore their role in non-canonical mutations.
